Metronidazole
Metronidazol is an antibiotic.[1][2] Metronidazol has a wide range of infections it can be used to treat.[3][2]
Theory[edit | edit source]
Evidence[edit | edit source]
No clinical trials of metronidazole have been done for chronic fatigue syndrome.
Metronidazole is FDA-approved for:
- protozoal infections such as Trichomoniasis vaginalis, Entamoeba histolytica, Giardia lamblia, blastocysts, and Balantidium coli.
- anaerobic bacterial infections caused by Bacteroides species, Fusobacterium species, Clostridium species, Gardnerella vaginalis, Helicobacter pylori, Prevotella species, Porphyromonas species, and Biophilia Wadsworth.[3]
Metronidazole is FDA-approved and widely used to treat a broad range of infections including intestinal amebiases, liver amebiasis, bacterial septicemia, bone and joint infections, central nervous system infections (e.g., meningitis and brain abscess), endocarditis, gynecologic infections (e.g., endometritis, tubo-ovarian abscess, bacterial vaginosis), intra-abdominal infections, lower respiratory tract infections, skin structure infections, and as a preventative drug before colorectal surgery.[3]
In a study comparing rifaximin to metronidazole, the overall prevalence of adverse events was significantly lower in the rifaximin group than the metronidazole group. Rifaximin showed a higher SIBO decontamination rate than metronidazole. But neither of the drugs seemed to represent a good choice for the management of patients affected by SIBO.[4]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Cost and availability[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
- Metronidazole - drugs.com
- How and when to take metronidazole - NHS
References[edit | edit source]
- ↑ "Metronidazole: Uses, Dosage, Side Effects, Warnings". Drugs.com. Retrieved December 9, 2023.
- ↑ 2.0 2.1 "How and when to take or use metronidazole". National Health Service. December 14, 2021. Retrieved December 9, 2023.
- ↑ 3.0 3.1 3.2 Weir, Connor B.; Le, Jacqueline K. (2023). Metronidazole. Treasure Island (FL): StatPearls Publishing. PMID 30969550.
- ↑ Lauritano, E. C.; Gabrielli, M.; Scarpellini, E.; Ojetti, V.; Roccarina, D.; Villita, A.; Fiore, E.; Flore, R.; Santoliquido, A.; Tondi, P.; Gasbarrini, G. (2009). "Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole". European Review for Medical and Pharmacological Sciences. 13 (2): 111–116. ISSN 1128-3602. PMID 19499846.
